Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Recurrence 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 5fludarabine phosphate 4Azacitidine 4Gemtuzumab 3Decitabine 3Cytarabine 3Busulfan 3venetoclax 2Thiotepa 2Radiotherapy 2Methylprednisolone 2Melphalan 2Filgrastim 2Etoposide 2Antilymphocyte Serum 2vosaroxin 1vedolizumab 1tipifarnib 1midostaurin 1imetelstat 1cedazuridine 1baricitinib 1Whole-Body Irradiation 1Tretinoin 1Tacrolimus 1Stem Cell Transplantation 1Nuclear Receptor Subfamily 4, Group A, Member 2 1Nivolumab 1Methotrexate 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Myelodysplastic Syndromes × Abatacept × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡